RT info:eu-repo/semantics/article
T1 Agentes inmunomoduladores (IMiDs): herramientas para el tratamiento del mieloma múltiple
T2 Immunomodulator drugs for the treatment of multiple myeloma
A1 Fernández Lázaro, Diego
A1 Fernández Lázaro, César I.
A1 Caballero García, Alberto
A1 Córdova Martínez, Alfredo
K1 Multiple myeloma - Treatment
K1 Multiple myeloma - Diagnosis
K1 Immunology
K1 Dexamethasone
K1 Neoplasm
K1 3207.13 Oncología
K1 3207.08 Hematología
AB Thalidomide changed the treatment of patients with multiple myeloma, however, its effectiveness has been compromised due to its side effects. New strategies are needed to specifically target the challenges of multiple myeloma through innovative, more effective, and less toxic therapy. The new immunomodulatory (IMiDs) compounds are structural and functional analogs of thalidomide, whichwere designed to improve the immunomodulatory and anticancer properties and tolerability profiles. We review the development of second generation IMiDs, lenalidomide and pomalidomide, their immunomodulatory and tumoricidal effects, their mechanisms of action, as well as the influence of dexamethasone on their effect and pharmacological resistance. In conclusion, lenalidomide andpomalidomide demonstrate a powerful activity and they are highly effective and well-tolerated treatment options for patients with myeloma, used alone or in combination with dexamethasone.
PB Sociedad Médica de Santiago
SN 0034-9887
YR 2018
FD 2018
LK https://uvadoc.uva.es/handle/10324/57728
UL https://uvadoc.uva.es/handle/10324/57728
LA spa
NO Revista médica de Chile, 2018; Vol. 146, Nª 12, págs. 1444-1451
NO Producción Científica
DS UVaDOC
RD 24-abr-2024